CLINICAL SIGNIFICANCE OF MR2 AT ONE YEAR AND BEYOND: A GIMEMA CML WP ANALYSIS ON 559 CML PATIENTS TREATED FRONTLINE WITH IMATINIB MESYLATE
F. Castagnetti,G. Gugliotta,M. Breccia,F. Stagno,A. Iurlo,F. Albano,E. Abruzzese,B. Martino,L. Levato,T. Intermesoli,P. Pregno,M. D'Adda,E. Calistri,S. Rupoli,F. Cavazzini,D. Ferrero,G. Caocci,M. Bocchia,M. Tiribelli,E. Montefusco,F. Sora,M. Bonifacio,C. Elena,S. Soverini,R. Foa,M. Cavo,F. Pane,G. Saglio,M. Baccarani,G. Rosti HAEMATOLOGICA（2019）
AI 理解论文
溯源树
样例
